获得性大疱表皮松解症患者创面管理的研究进展

doi:10.3761/j.issn.0254-1769.2023.12.016

摘要/Abstract

摘要：

获得性大疱表皮松解症是以全身散发性水疱和黏膜糜烂为主要表现的罕见自身免疫性疾病，创面综合管理通过用药护理、创面护理、预防损伤、营养支持及合并症护理等方法促进创面愈合，减轻患者不适症状，提高患者生活质量。该文从获得性大疱表皮松解症的分型、创面评估工具、影响创面愈合的因素、创面综合管理方法进行综述，旨在为完善国内相关研究及提高护理实践质量提供参考。

关键词: 获得性大疱表皮松解症, 创面护理, 综述

Abstract:

Epidermolysis bullosa acquisita is a rare autoimmune blistering disease with bullae formation on the skin and erosions on the mucous membranes. Integrated wound management promotes wound healing，reduces patient discomfort，and improves patient quality of life through medication care，wound care，injury prevention，nutritional support，and comorbidity care.This paper reviewed the staging of epidermolysis bullosa acquisita，wound assessment tools，factors affecting wound healing，and integrated wound management methods，with the aim of providing a reference for improving related research and improving the quality of nursing practice in China.

Key words: Epidermolysis Bullosa Acquisita, Wound Care, Review

周子怡, 王飞霞, 潘喆, 李卫珍, 钟紫凤. 获得性大疱表皮松解症患者创面管理的研究进展[J]. 中华护理杂志, 2023, 58(12): 1517-1522.

ZHOU Ziyi, WANG Feixia, PAN Zhe, LI Weizhen, ZHONG Zifeng. Research progress of wound care in patients with epidermolysis bullosa acquisita[J]. Chinese Journal of Nursing, 2023, 58(12): 1517-1522.

参考文献 45

[1]	Kridin K, Kneiber D, Kowalski EH, et al. Epidermolysis bullosa acquisita:a comprehensive review[J]. Autoimmun Rev, 2019, 18(8):786-795. DOI URL
[2]	Schmidt E, Zillikens D. Pemphigoid diseases[J]. Lancet, 2013, 381(9863):320-332. DOI PMID
[3]	Bruckner AL, Losow M, Wisk J, et al. The challenges of living with and managing epidermolysis bullosa:insights from patients and caregivers[J]. Orphanet J Rare Dis, 2020, 15(1):1. DOI PMID
[4]	Padniewski JJ, Shaver RL, Schultz B, et al. Patient quality of life improvement in bullous disease:a review of primary literature and considerations for the clinician[J]. Clin Cosmet Investig Dermatol, 2022, 15:27-42. DOI URL
[5]	Pourali SP, Gutierrez Y, Kohn AH, et al. Bullous dermatoses and depression:a systematic review[J]. JAMA Dermatol, 2021, 157(12):1487-1495. DOI PMID
[6]	Koga H, Prost-Squarcioni C, Iwata H, et al. Epidermolysis bul-losa acquisita:the 2019 update[J]. Front Med(Lausanne), 2019,5.
[7]	Iwata H, Vorobyev A, Koga H, et al. Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients[J]. Orphanet J Rare Dis, 2018, 13(1):153. DOI PMID
[8]	Murrell DF, Daniel BS, Joly P, et al. Definitions and outcome measures for bullous pemphigoid:recommendations by an international panel of experts[J]. J Am Acad Dermatol, 2012, 66(3):479-485. DOI PMID
[9]	Masmoudi W, Vaillant M, Vassileva S, et al. International validation of the Bullous Pemphigoid Disease Area Index Severity Score and calculation of cut-off values for defining mild,moderate and severe types of bullous pemphigoid[J]. Br J Dermatol, 2021, 184(6):1106-1112. DOI PMID
[10]	Cole EF, Mustin DE, Feldman RJ. The effect of skin colour and Fitzpatrick skin type on Bullous Pemphigoid Disease Area Index(BPDAI) scores[J]. Br J Dermatol, 2022, 187(4):606-607. DOI URL
[11]	Loh CC, Kim J, Su JC, et al. Development,reliability,and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index(EBDASI)[J]. J Am Acad Dermatol, 2014, 70(1):89-97. DOI URL
[12]	Jain SV, Harris AG, Su JC, et al. The Epidermolysis Bullosa Disease Activity and Scarring Index(EBDASI):grading disease severity and assessing responsiveness to clinical change in epidermolysis bullosa[J]. J Eur Acad Dermatol Venereol, 2017, 31(4):692-698. DOI PMID
[13]	Moss C, Wong A, Davies P. The Birmingham Epidermolysis Bullosa Severity Score:development and validation[J]. Br J Dermatol, 2009, 160(5):1057-1065. PMID
[14]	Lee SE, Lee SJ, Kim SE, et al. Intravenous allogeneic umbili-cal cord blood-derived mesenchymal stem cell therapy in re-cessive dystrophic epidermolysis bullosa patients[J]. JCI In-sight, 2021, 6(2).
[15]	Esposito S, Guez S, Orenti A, et al. Autoimmunity and cyto-kine imbalance in inherited epidermolysis bullosa[J]. Int J Mol Sci, 2016, 17(10).
[16]	Bruckner AL, Fairclough DL, Feinstein JA, et al. Reliability and validity of the instrument for scoring clinical outcomes of research for epidermolysis bullosa(iscorEB)[J]. Br J Dermatol, 2018, 178(5):1128-1134. DOI PMID
[17]	魏宗婷, 陈旭光. 大疱性表皮松解坏死型药疹的临床观察与护理[J]. 护理研究, 2017, 31(30):3865-3866.
	Wei ZT, Chen XG. Clinical observation and nursing of epi-dermolysis bullosa necrotizing type of drug eruption[J]. Chin Nurs Res, 2017, 31(30):3865-3866.
[18]	Hignett E, Sami N. Pediatric epidermolysis bullosa acquisita:a review[J]. Pediatr Dermatol, 2021, 38(5):1047-1050. DOI PMID
[19]	Chen M, O’Toole EA, Sanghavi J, et al. The epidermolysis bul-losa acquisita antigen(type Ⅶ collagen) is present in human colon and patients with Crohn’s disease have autoantibodies to type Ⅶ collagen[J]. J Invest Dermatol, 2002, 118(6):1059-1064. PMID
[20]	Ormaechea-Pérez N, Tuneu-Valls A, Borja-Consigliere HA, et al. Peristomal epidermolysis bullosa acquisita in a patient with Crohn’s disease[J]. Acta Derm Venereol, 2014, 94(4):489-490. DOI URL
[21]	Kridin K. Subepidermal autoimmune bullous diseases:overview,epidemiology,and associations[J]. Immunol Res, 2018, 66(1):6-17. DOI URL
[22]	Salera S, Tadini G, Rossetti D, et al. A nutrition-based approach to epidermolysis bullosa:causes,assessments,requirements and management[J]. Clin Nutr, 2020, 39(2):343-352. DOI URL
[23]	Stoj V, Lu J. Nutrition and bullous diseases[J]. Clin Dermatol, 2022, 40(2):156-165. DOI URL
[24]	Chen J, Mao X, Zhao W, et al. Assessment of the characteristics and associated factors of infectious complications in bullous pemphigoid[J]. Front Immunol, 2020, 11:1607. DOI PMID
[25]	Phoon YW, Fook-Chong SM, Koh HY, et al. Infectious complications in bullous pemphigoid:an analysis of risk factors[J]. J Am Acad Dermatol, 2015, 72(5):834-839. DOI PMID
[26]	Khan MT, O’Sullivan M, Faitli B, et al. Creating new guidelines on how best to treat foot symptoms in people with EB[J]. Br J Dermatol, 2020, 182(3):e89-e114.
[27]	Dewan AK, Braue J, Danford B, et al. In utero development of epidermolysis bullosa acquisita[J]. Pediatr Dermatol, 2019, 36(1):E46-E47. DOI
[28]	Kim JH, Kim YH, Kim SC. Epidermolysis bullosa acquisita:a retrospective clinical analysis of 30 cases[J]. Acta Derm Ve-nereol, 2011, 91(3):307-312.
[29]	Rousseau A, Prost-Squarcioni C, Doan S, et al. Ocular involvement in epidermolysis bullosa acquisita with long-term follow-up[J]. Br J Ophthalmol, 2020, 104(2):235-240. DOI PMID
[30]	Pope E, Lara-Corrales I, Mellerio J, et al. A consensus approach to wound care in epidermolysis bullosa[J]. J Am Acad Dermatol, 2012, 67(5):904-917. DOI PMID
[31]	El HM, Zambruno G, Bourdon-Lanoy E, et al. Multicentre consensus recommendations for skin care in inherited epidermolysis bullosa[J]. Orphanet J Rare Dis, 2014, 9:76. DOI PMID
[32]	Fernandez R, Green HL, Griffiths R, et al. Water for wound cleansing[J]. Cochrane Database Syst Rev, 2022, 9(9):D3861.
[33]	张媛, 郭锦丽. 沉浸式虚拟现实技术在创面操作性疼痛管理中的应用进展[J]. 中华护理杂志, 2023, 58(2):243-249. DOI URL
	Zhang Y, Guo JL. Application progress of immersive virtual reality technology in wound procedural pain management[J]. Chin J Nurs, 2023, 58(2):243-249. DOI URL
[34]	Mellerio JE, El HM, Bellon N, et al. Emergency management in epidermolysis bullosa:consensus clinical recommendations from the European reference network for rare skin diseases[J]. Orphanet J Rare Dis, 2020, 15(1):142. DOI PMID
[35]	Viana MC, Xavier C, Cobrado L. Disinfection methods against SARS-CoV-2:a systematic review[J]. J Hosp Infect, 2022, 119:84-117. DOI URL
[36]	Oropallo A, Snyder RJ, Karpf A, et al. Quality of life improvement in patients with hard-to-heal leg wounds treated with Prontosan wound irrigation solution and wound gel[J]. J Wound Care, 2021, 30(10):854-865. DOI PMID
[37]	于倩, 关红, 王秋节. 1例大疱性表皮松解坏死症患者的创面处理及护理[J]. 中国实用护理杂志, 2015, 31(6):429-431.
	Yu Q, Guan H, Wang QJ. Wound management and care of a patient with epidermolysis bullosa necrosis[J]. Chin J Prac Nurs, 2015, 31(6):429-431.
[38]	肖娓珠, 林翠芬, 陈淑萍. 25例大疱性表皮坏死松解型药疹患者皮肤黏膜应用聚维酮碘喷雾及湿性敷料换药的护理[J]. 中华护理杂志, 2014, 49(11):1359-1362.
	Xiao WZ, Lin CF, Chen SP. Nursing care of skin and mucosa with povidone-iodine spray and moist dressing in 25 patients with bullous epidermal necrolysis drug eruption[J]. Chin J Nurs, 2014, 49(11):1359-1362.
[39]	王春立, 吴心怡, 陈芳娇, 等. 1例大疱性表皮松解症患儿异基因造血干细胞移植的护理[J]. 中华护理杂志, 2017, 52(6):757-760.
	Wang CL, Wu XY, Chen FJ, et al. Nursing care of a child patient with epidermolysis bullosa receiving hematopoietic stem cell transplantation[J]. Chin J Nurs, 2017, 52(6):757-760.
[40]	Watanobe I, Kida H, Sekine Y, et al. Safe skin management during open hepatectomy in a patient with recessive dystrophic congenital epidermolysis bullosa[J]. Case Rep Surg, 2018, 2018:1786786.
[41]	Stevens LJ, Mckenna S, Marty J, et al. Understanding the outcomes of a home nursing programme for patients with epidermolysis bullosa:an Australian perspective[J]. Int Wound J, 2016, 13(5):863-869. DOI PMID
[42]	朱小妹, 谌永毅, 韦迪, 等. 新型冠状病毒肺炎疫情下基于互联网平台的慢性伤口居家照护体系构建与实践[J]. 中华护理杂志, 2020, 55(S1):799-802.
	Zhu XM, Chen YY, Wei D, et al. Construction and practice of home care system for chronic wound based on internet platform under the prevalence of coronavirus disease 2019[J]. Chin J Nurs, 2020, 55(S1):799-802.
[43]	Khan MT, O’Sullivan M, Faitli B, et al. Foot care in epider-molysis bullosa:evidence-based guideline[J]. Br J Dermatol, 2020, 182(3):593-604. DOI PMID
[44]	费超男, 段培蓓, 杨玲, 等. 胃癌患者围手术期营养管理的最佳证据总结[J]. 中华护理杂志, 2022, 57(19):2345-2352. DOI URL
	Fei CN, Duan PB, Yang L, et al. Evidence summary of nutritional management in patients with gastric cancer during the perioperative period[J]. Chin J Nurs, 2022, 57(19):2345-2352. DOI URL
[45]	Hubbard LD. Long-term outcomes in adults with recessive dys-trophic epidermolysis bullosa fed by a gastrostomy tube in situ[J]. Int J Dermatol, 2016, 55(2):181-186. DOI PMID